Eli Lilly Raises FY 2026 Revenue Outlook; Shares Hit Record High
Eli Lilly raised its full-year 2026 revenue outlook after better-than-expected third-quarter earnings. Shares climbed 5.2% in premarket trading to all-time highs.
Story updates
12:44:02 PM UTC
SquawkNews
PUNTO 2-AGGIORNAMENTO 1-Eli Lilly rivede al rialzo le previsioni sui ricavi grazie alle vendite di f
12:44:04 PM UTC
SquawkNews
更新版 2-更新 1-禮來公司因減肥藥銷售表現強勁而上調營收預期，但因交易相關費用而下調利潤預期 禮來將全年營收預期上調至最高920億美元 減肥藥Mounjaro和Zepbound助力第三季度業績超預
12:44:07 PM UTC
SquawkNews
FOKUS 2-Update 1-Eli Lilly hebt die Umsatzprognose aufgrund der Verkäufe von Medikamenten zur Gewich
12:44:09 PM UTC
SquawkNews
종합 2-업데이트 1-일라이 릴리, 체중 감량제 매출 호조에 힘입어 매출 전망치를 상향 조정했으나, 인수 관련 비용으로 인해 이익 전망치는 하향 조정 릴리, 연간 매출 전망치를 최
12:44:17 PM UTC
SquawkNews
UPDATE 2-更新 1-イーライ・リリー、減量薬で売上見通し上げ、買収費用で利益見通し下げ リリー、通期の売上高予想を最大920億ドルに上方修正 減量薬「ムンジャロ」と「ゼップバウンド」が第３・四
12:44:29 PM UTC
SquawkNews
ATUALIZA 3-Eli Lilly eleva previsão de receita devido às vendas de medicamentos para emagrecimento,
Shares of Eli Lilly (LLY) climbed 5.2% in premarket trading on Thursday, tracking all-time highs, after the pharmaceutical behemoth raised its full-year 2026 revenue outlook following better-than-expected third-quarter earnings, driven by strong demand for its diabetes and weight-loss drugs.CEO Dav…